Clinical Trials Logo

Clinical Trial Summary

To test the feasibility of a clinical trial implementing I-CAT, a novel therapeutic intervention combining strategies to improve stress reactivity and increase meaningful coping, as well as a range of possible proximal (e.g. autonomic, endocrine, immune indices of stress reactivity, symptom severity) and distal measures (function, relapse, quality of life) for 40 people with first episode psychosis in the context of a small randomized controlled trial.


Clinical Trial Description

Schizophrenia is one of the most devastating disorders that often results in a lack of functional recovery. Current treatments focused on remediating symptoms have shown only small successes in a return to functioning despite evidence of a dysregulated stress response. There is a fundamental gap in understanding the impact of allostatic overload in persons with schizophrenia that the investigators theorize is associated with deficits in functioning and with an increased vulnerability and relapse risk. The long-term goal is to test an intervention aimed at improving stress reactivity. The objective in this application is to develop and test the feasibility of a novel therapeutic intervention combining strategies to improve stress reactivity and increase meaningful coping. The central hypothesis is that an intervention that improves stress reactivity as measured proximally by endocrine, immune, and autonomic indices will result in improved adaptive capacity, better role functioning, reduced risk of relapse, and decreased likelihood of disability for people in the early stages of schizophrenia. The rationale for the proposed research is that stress reactivity may be a modifiable risk factor underlying functional deficits in schizophrenia. The intervention integrates two treatment approaches. The first is based on research showing that mindfulness meditation practice is associated with alterations in the neural processing of stressful events and targets adaptive responses to stress. The second focuses on providing a buffer against stress by using the self-generation of adaptive emotions with a positive psychology intervention, which is potentially associated with building protective social resources. These complimentary interventions provide a comprehensive synergistic approach for this population that could lead to more adaptive coping responses and create a buffer against stress ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03067311
Study type Interventional
Source University of North Carolina, Chapel Hill
Contact
Status Completed
Phase N/A
Start date October 3, 2016
Completion date March 30, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT04298450 - ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention N/A
Completed NCT00419146 - Treatment of Schizophrenia With an Omega-3 Fatty Acid (EPA) and Antioxidants Phase 2/Phase 3
Not yet recruiting NCT05974527 - Pilot Study 1: Efficacy and Safety of Sublingual Dexmedetomidine (BXCL501) for the Treatment of Agitation in the Emergency Department Phase 4
Recruiting NCT06423651 - Benefits of Combining MCT With CR in the Recovery of Patients With Psychotic Spectrum Disorders N/A
Recruiting NCT04113993 - Bazedoxifene -Treatment for Women With Schizophrenia Phase 4
Completed NCT06041646 - Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder Phase 4
Completed NCT04418011 - Neuromodulation of Social Cognitive Circuitry in People With Schizophrenia Spectrum Disorders N/A
Active, not recruiting NCT05658510 - Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III) Phase 3
Terminated NCT00515489 - Study on the Safety and Effectiveness of Risperidone Treatment of Acute Psychotic Patients N/A
Recruiting NCT05877716 - EPI-MINN: Targeting Cognition and Motivation - National N/A
Completed NCT03079024 - Minnesota Community-Based Cognitive Training in Early Psychosis N/A
Completed NCT03559426 - Research Into Antipsychotic Discontinuation and Reduction Trial Phase 4
Recruiting NCT05756855 - Young Adults With Violent Behavior During Early Psychosis N/A
Recruiting NCT04497857 - Academic-Community EPINET (AC-EPINET) N/A
Recruiting NCT05109065 - Peripheral Immune System in Individuals With Schizophrenia
Completed NCT03187769 - Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder Phase 3
Recruiting NCT03632278 - Mindfulness Psychoeducation Program for Schizophrenia N/A
Completed NCT01082588 - Effects of Pravastatin on Cholesterol, Inflammation and Cognition in Schizophrenia Phase 4
Recruiting NCT05538832 - Remote State Representation in Early Psychosis Early Phase 1
Recruiting NCT06002958 - Horyzons: Implementation and Integration in Clinical Practice N/A